Oxford Expression Technologies baculoFECTIN transfection reagent

Tuesday, 19 April, 2011 | Supplied by: BioNovus Life Sciences


Oxford Expression Technologies has launched baculoFECTIN, a non-toxic transfection reagent optimised for use in insect cells and proven to produce greater levels of transfection - leading to high-level protein expression.

Although optimised for insect cell lines such as Sf9, Sf21 and T.ni, the reagent’s transfection spectrum comprises various established cell lines and primary cells. The reagent consists of two components, a positively charged polymer with DNA-binding capacity that is embedded into a novel porous nanoparticle. The complete nanoparticle complex protects the bound DNA from degradation by nucleases. Only the DNA-nanoparticle complex with its unique size can be preferentially taken up by the cells. Within the cells, the released DNA-nanoparticle complexes are protected against DNA degradation.

The main benefits of the reagent compared with lipid-based products are that it has a quick, effective and easy protocol - minimising the time to produce high-titre seed stock.

It is non-toxic, hence cell health and viability is maintained, plus the nanoparticle/polymer duplex optimises entry into cells and stabilises the DNA within transfected insect cells.

Stable for up to a year, the reagent is a companion to the flashBAC baculovirus expression system and is suitable for high-throughput transfection experiments.

Online: www.bionovuslifesciences.com.au
Phone: 02 9484 0931
Related Products

Biosensis MAP2 antibodies

Biosensis's validated MAP2 antibodies are designed to help users identify MAP2, whether they...

Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

The antibodies are specific to CTC surface markers to enable the sensitive and specific...

Microbiologics UV-BioTAG QC microorganisms for quality control testing

UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd